Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)
- Posted Date: December 16, 2014
- Open Date (Earliest Submission Date): February 6, 2015
- Letter of Intent Due Date(s): Not Applicable
- Application Due Date(s): The first due date for all types of applications allowed for this FOA is March 6, 2015. Thereafter Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- AIDS Application Due Date(s): Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Scientific Merit Review: Standard dates apply
- Advisory Council Review: Standard dates apply
- Earliest Start Date: Standard dates apply
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem. The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate the following examples, among others: (a) current commercially supported systems, (b) next-generation systems, (c) quality assurance and quality control, (d) validation and correlation studies, (e) quantitative imaging, and (f) related research resources. Because applications should be translational in scope, this FOA defines innovation as a coherent translational plan to deliver emerging or new capabilities for preclinical or clinical use that are not yet broadly employed in preclinical or clinical settings. In addition, innovation may be considered as delivery of a new capability to end users. The partnership on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate their system to solve their chosen cancer problem. This FOA will support clinical trials that test functionality, optimize, and validate the performance of the proposed translational work. This FOA does not intend to support either actual commercial production or basic research projects that do not emphasize translation.